TY - JOUR
T1 - Soluble copolymer of wasp venom with human albumin for venom immunotherapy
AU - Gewurz, Anita
AU - Grammer, Leslie C.
AU - Shaughnessy, Martha A.
AU - Patterson, Roy
N1 - Funding Information:
From the Section of Allergy and Immunology, Department of Med-icine, Northwestern University Medical School, Chicago, Ill. Supported by the Ernest S. Bazley Grant and United States Public Health Service Grant AI 11403. Received for publication May 17, 1985. Accepted for publication Oct. 16, 1985. Reprint requests: Roy Patterson, M.D., 303 E. Chicago Ave., Chi-cago, IL 60611. *Summary of data from BB-IND 1292 clinical studies, 1978 to 1979, on HoHister-Stier products (unpublished data).
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1986/3
Y1 - 1986/3
N2 - Polymerization of allergens decreases allergenicity while retaining immunogenicity, as we have demonstrated for ragweed, grass, and tree pollens. We have also polymerized bee venom with human albumin to form soluble, high-molecular-weight copolymers that are immunogenic in rabbits. We now have prepared a soluble wasp venom-albumin polymer (WVAP), molecular weight ≥240,000 daltons, by glutaraldehyde treatment and Sephacryl S-300 column fractionation. Rabbits immunized with WVAP produced IgG to both WVAP and wasp venom (WV), as measured by ELISA. IgG against WVAP was totally inhibitable by a mixture of WV and albumin, demonstrating both retention of native antigens and absence of new antigenic determinants in WVAP. IgG against WV in serum from patients receiving maintenance doses of WV immunotherapy was inhibited by WVAP. In summary, we have synthesized a soluble, high-molecular-weight copolymer of WV that retains the immunogenicity of native WV, contains no new antigenic determinants, and has potential value in the treatment of patients with WV anaphylaxis.
AB - Polymerization of allergens decreases allergenicity while retaining immunogenicity, as we have demonstrated for ragweed, grass, and tree pollens. We have also polymerized bee venom with human albumin to form soluble, high-molecular-weight copolymers that are immunogenic in rabbits. We now have prepared a soluble wasp venom-albumin polymer (WVAP), molecular weight ≥240,000 daltons, by glutaraldehyde treatment and Sephacryl S-300 column fractionation. Rabbits immunized with WVAP produced IgG to both WVAP and wasp venom (WV), as measured by ELISA. IgG against WVAP was totally inhibitable by a mixture of WV and albumin, demonstrating both retention of native antigens and absence of new antigenic determinants in WVAP. IgG against WV in serum from patients receiving maintenance doses of WV immunotherapy was inhibited by WVAP. In summary, we have synthesized a soluble, high-molecular-weight copolymer of WV that retains the immunogenicity of native WV, contains no new antigenic determinants, and has potential value in the treatment of patients with WV anaphylaxis.
UR - http://www.scopus.com/inward/record.url?scp=0022626458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022626458&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(86)90189-2
DO - 10.1016/0091-6749(86)90189-2
M3 - Article
C2 - 2419385
AN - SCOPUS:0022626458
SN - 0091-6749
VL - 77
SP - 520
EP - 523
JO - The Journal of allergy and clinical immunology
JF - The Journal of allergy and clinical immunology
IS - 3
ER -